| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADAMTS14 |
| Uniprot No | Q8WXS8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 253-555aa |
| 氨基酸序列 | HAKPGSYSIEVLLVVDDSVVRFHGKEHVQNYVLTLMNIVDEIYHDESLGVHINIALVRLIMVGYRQSLSLIERGNPSRSLEQVCRWAHSQQRQDPSHAEHHDHVVFLTRQDFGPSGYAPVTGMCHPLRSCALNHEDGFSSAFVIAHETGHVLGMEHDGQGNGCADETSLGSVMAPLVQAAFHRFHWSRCSKLELSRYLPSYDCLLDDPFDPAWPQPPELPGINYSMDEQCRFDFGSGYQTCLAFRTFEPCKQLWCSHPDNPYFCKTKKGPPLDGTECAPGKWCFKGHCIWKSPEQTYGQDGGW |
| 预测分子量 | 40.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADAMTS14重组蛋白的模拟参考文献示例(注：内容为虚构，仅供格式参考)：
1. **文献名称**：*重组ADAMTS14蛋白的表达及其在胶原加工中的功能研究*
**作者**：Smith J, et al.
**摘要**：本研究通过哺乳动物细胞系统成功表达并纯化了重组ADAMTS14蛋白，证实其能够特异性切割前胶原的N端肽，揭示了其在胶原纤维组装中的潜在调控作用。
2. **文献名称**：*ADAMTS14重组酶的生化特性及底物特异性分析*
**作者**：Chen L, et al.
**摘要**：通过体外酶活实验，作者发现重组ADAMTS14对Ⅲ型胶原的降解活性显著高于其他胶原类型，并鉴定其活性依赖锌离子及特定pH环境，为开发相关抑制剂提供依据。
3. **文献名称**：*ADAMTS14重组蛋白在皮肤纤维化模型中的治疗潜力*
**作者**：Wang Y, et al.
**摘要**：在小鼠皮肤纤维化模型中，外源性重组ADAMTS14蛋白显著减少胶原过度沉积，提示其可能通过调控细胞外基质重塑缓解纤维化疾病进展。
4. **文献名称**：*ADAMTS14重组表达系统的优化及结构解析*
**作者**：Garcia R, et al.
**摘要**：采用杆状病毒-昆虫细胞系统优化ADAMTS14重组蛋白产量，并通过冷冻电镜获得其空间结构，揭示了其底物结合域的关键氨基酸残基。
(注：以上文献及摘要均为模拟创作，实际研究中请通过学术数据库查询真实文献。)
ADAMTS14 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 14) is a member of the ADAMTS protease family, known for its role in extracellular matrix (ECM) remodeling and tissue development. This secreted zinc-dependent enzyme shares structural homology with other ADAMTS members, featuring a prodomain, catalytic domain, disintegrin-like domain, thrombospondin type-1 repeats (TSR), and a C-terminal ancillary domain. Unlike some family members implicated in collagen processing (e.g., ADAMTS2/3), ADAMTS14 is proposed to function as a procollagen N-proteinase, potentially cleaving type III collagen precursors to facilitate fibril assembly, though its substrate specificity remains less characterized.
Recombinant ADAMTS14 protein is typically produced in mammalian or insect expression systems to ensure proper post-translational modifications. Its recombinant form enables studies on enzymatic kinetics, substrate interactions, and regulatory mechanisms. Research suggests ADAMTS14 involvement in connective tissue disorders, fibrosis, and cancer progression, where abnormal ECM dynamics contribute to pathogenesis. For example, upregulated ADAMTS14 expression has been observed in fibrotic liver tissues and certain tumors, hinting at its potential as a therapeutic target or biomarker.
Despite progress, key knowledge gaps persist. The enzyme's physiological regulation, precise in vivo substrates, and structural determinants of activity are incompletely understood. Recombinant protein tools have been instrumental in mapping cleavage sites and developing activity assays. Recent studies also explore its interplay with cytokines like TGF-β in fibrotic pathways. However, conflicting reports on its collagenolytic efficiency compared to ADAMTS2/3 underscore the need for further mechanistic studies. As a recombinant reagent, ADAMTS14 facilitates drug discovery efforts, particularly in screening inhibitors for fibrotic or metastatic diseases, while ongoing structural work aims to clarify its unique functional attributes within the ADAMTS family.
×
